Y. Vugmeyster, X. Xu, F. P. Theil, L. Khali, and M. Leach, Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges, World Journal of Biological Chemistry, vol.3, issue.4, pp.73-92, 2012.
DOI : 10.4331/wjbc.v3.i4.73

A. Baumann, Early Development of Therapeutic Biologics - Pharmacokinetics, Current Drug Metabolism, vol.7, issue.1, pp.15-21, 2006.
DOI : 10.2174/138920006774832604

A. Supersaxo, W. R. Hein, and H. Steffen, Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration, Pharmaceutical Research, vol.07, issue.2, pp.167-176, 1990.
DOI : 10.1023/A:1015880819328

L. Zhao, T. Ren, and D. Wang, Clinical pharmacology considerations in biologics development, Acta Pharmacologica Sinica, vol.87, issue.11, pp.1339-1347
DOI : 10.1038/aps.2012.51

T. Prueksaritanont and C. Tang, ADME of biologics-What Have We Learned from Small Molecules ?; The AAPS Journal, pp.410-41905, 2012.

E. and 2. Référencechmp, Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues EMA, 2010.

V. Azevedo, Biosimilars require scientifically reliable comparative clinical data, Revista Brasileira de Reumatologia (English Edition), vol.53, issue.1
DOI : 10.1016/S2255-5021(13)70013-0

A. and A. Health, System Pharmacist's Guide to Biosimilars: Regulatory, Scientific, and Practical Considerations ; Disponible sur http

M. Benhalima, Les copies du Lovenox sont elles à considérer comme des génériques ou des biosimilaires ? ; Société Algérienne de Médecine Vasculaire 2009 disponible sur http

J. Bernard and . Biomedicaments-en-france, Leem : les entreprises du médicament ; Septembre2013, Etat des lieux, 2014.

. Biotecanada, Démystifier les médicaments biosimilaires : Guide à l'intention des rédacteurs scientifiques ; Disponible sur http

C. and A. Rendu, disponible sur http://ansm.sante.fr/S-informer/Actualite/Abasria-insuline-glargine- Clopidogrel-ASATeva-Daklinza-daclastavir-Velphoro-Vizamyl-flutemetamol- f-18-Triumeq-abacavir-dolutegravir-lamivudine-retour-sur-la-reunion-de-juin- 2014-du-CHMP-Point-d-information consulté le 02, Juin, vol.08, 2014.

D. Hartl and E. Jones, Génétiques les grands principes 3eme Ed. ; Dunod ; Sciences Sup, 2003.

I. Guideline and E. , Comparability of biotechnological/biological products subject to change in their manufacturing process IMS Health, analyse développement & Conseil, 2008.

J. Wp, Assays Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization profiles of Generics Copies of Enoxaparin, Blood (ASH Annual Meeting Abstracts) 2006 108 Poster Board #-Session, p.36

R. Kaiser, Comparability Studies : The Keys to a Biosimilar's Success ; Biopharmaceutical Solution ; Covance Webinar

. Pharmacie, le-lovenox-de-sanofi-generique-aux-etats- unis, pp.28-35

C. Lepen, Les biosimilaires en 15 questions Disponible sur http://www.apmnews.com/Documents/lesbiosimilairesen15questionsemail, Avril, vol.08, 2014.

P. Lloyd, Challenges in early clinical development of biologics : Mars 2011 ; disponible sur http, 2014.

I. Mief&, Copies des médicaments issus de biotechnlogies (« biosimialire ») : l'agence européenne évolue timidement vers plus de pragmatisme ; Réponse conjointe à la consultation de l'EMA ; 31 Octobre 2013 disponible sur http, 2014.

A. Moreau, Des médicaments issus des biotechnologies aux médicaments biosimilaires: Etat des lieux, Ansm.sante.fr consulté le 28, 2011.

A. Moreau, Médicaments biosimilaires : Etat des lieux, 2013.

D. Pinheiro, Bilan 2012 sur l'utilisation des biosimilaires : un équivalent du biomédicament de référence ou un générique biologique ?, Th D Pharm, 2012.

J. Rovira, J. Espin, L. Garcia, and A. Olry-de-labry, The impact of biosimilars's entry in the EU market ; Eminet, Janvier, 2011.

. Sanofi-aventis, Disponible sur http://www.sanofi.com/Images/14182_080515-2_LOVENOX_USA_pdf, pp.28-35, 2008.

F. Serusclat, . Génomique, and . Informatique, L'impact sur les thérapies et sur l'industrie pharmaceutique disponible sur http

P. Seymour, The Challenges of Demonstrating Comparability of Biosimilar Products ; Bio Process Technology Consultants, Bioprocess Theater, 2010.

L. Steffen and . Biomedicaments-en-france, Leem : les entreprises du médicament ; Septembre2013, Etat des lieux, 2013.

L. Steffen and . Biomedicaments-en-france, Leem : les entreprises du médicament, Etat des lieux Avril, vol.http, 2011.

J. Abraham, Developing Oncology Biosimilars : An Essential Approach for the future ; seminars in Oncology, Decembre Supp, vol.40, issue.1, pp.5-24, 2013.

C. Ahn and S. Lee, Statistical consideration in the design of biosimilar cancer clinical trials ; National Institute of Health Korea, pp.495-503, 2011.

V. Azevedo, Biosimilars require scientifically reliable comparative clinical data, Revista Brasileira de Reumatologia (English Edition), vol.53, issue.1, pp.127-131
DOI : 10.1016/S2255-5021(13)70013-0

M. Balaji, Use of pharmacokinetics/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics, British Journal Of Clinical Pharmacology, vol.67, issue.2, pp.153-160, 2008.

M. Baker, H. Reynolds, B. Lumicisi, and C. Bryson, Immunogenicity of protein therapeutics: The key causes, consequences and challenges, Self/Nonself, vol.1, issue.4, pp.314-322, 2010.
DOI : 10.4161/self.1.4.13904

A. Baumann, Early Development of Therapeutic Biologics - Pharmacokinetics, Current Drug Metabolism, vol.7, issue.1, pp.15-21, 2006.
DOI : 10.2174/138920006774832604

A. Berghout, Clinical programs in the development of similar biotherapeutic products: Rationale and general principles, Biologicals, vol.39, issue.5, pp.293-296, 2011.
DOI : 10.1016/j.biologicals.2011.06.024

C. Bennett, Pure Red-Cell Aplasia and Epoetin Therapy, New England Journal of Medicine, vol.351, issue.14, pp.1403-1408, 2004.
DOI : 10.1056/NEJMoa040528

F. Berthe, B. Banga, and C. Guignot, L'arrivée des anticorps changera-t-elle la donne ? ; Le pharmacien hôpital, Janvier, p.171, 2011.

S. Bhupinder and S. Vikrant, Biosimilars: an overview, Mars, pp.1-5, 2011.

E. Blackstone, J. Fuhr, and . Jr, Innovation and competition: will biosimilars succeed, BiotechnolHealthc, vol.9, pp.24-31, 2012.

P. Bogaert, E. Lietzan, and L. Sim, Biosimiliar regulation : Important consideration and global developments ; Cross Border Life Sciences Handbook, 2011.

K. Boven, S. Stryker, and J. Knight, The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes, Kidney International, vol.67, issue.6, pp.2346-2353, 2005.
DOI : 10.1111/j.1523-1755.2005.00340.x

S. Breslin, Cytokine-Release Syndrome: Overview and Nursing Implications, Clinical Journal of Oncology Nursing, vol.11, issue.0, pp.42-47, 2007.
DOI : 10.1188/07.CJON.S1.37-42

T. Brodniewicz-proba, The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products ; Drug research, pp.641-648, 2008.

L. Bui and C. Taylor, Developing Clinical Trials for Biosimilars ; Seminars in Oncology, FévrierS1, vol.41, pp.15-25, 2014.

J. Cortes and G. Curigliano, Expert perspectives on biosimilar monoclonal antibodies in breast cancer, Breast Cancer Research and Treatment, vol.86, issue.2, pp.233-239, 2014.
DOI : 10.1007/s10549-014-2879-9

D. Crobu, Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen??, BMC Pharmacology and Toxicology, vol.164, issue.5, p.7, 2014.
DOI : 10.1016/j.jconrel.2012.06.026

D. Crommelin, Pharmaceutical evaluation of biosimilars : important differences from generic low-molecular-weight pharmaceuticals, The European Journal of Hospital Pharmacy Science, vol.11, issue.1, pp.11-17, 2005.

D. Groot, A. S. Scott, and D. W. , Immunogenicity of protein therapeutics ; Trends Immunolo, pp.10-1016, 2007.

Z. Desanvicente-celis, A. Gomez-lopez, and J. Anaya, Similar biotherapeutic products: overview and reflections, Immunotherapy, vol.4, issue.12, pp.1841-1857, 2012.
DOI : 10.2217/imt.12.128

P. Declerk, Produits biologiques et biosimilaires : science et implications, J Pharm Clin, vol.2013, issue.321, pp.17-22

G. Dranitsaris, Clinical trial design in biosimilar drug development, Investigational New Drugs, vol.295, issue.337, pp.479-487, 2013.
DOI : 10.1007/s10637-012-9899-2

D. Fronzo and R. , Glucose clamp technique: a method for quantifying Insulin secretion and resistance, Am J Physiol, vol.237, pp.214-223, 1979.

M. G. Fari and U. Kralovanszky, P ; The founding father of biotechnology: Károly (Karl) Ereky, International Journal of Horticultural Science, vol.2006, issue.121, pp.9-12

M. Fletcher, Biosimilars clinical development program: Confirmatory clinical trials: A virtual/simulated case study comparing equivalence and non-inferiority approaches, Biologicals, vol.39, issue.5, pp.270-277, 2011.
DOI : 10.1016/j.biologicals.2011.06.004

J. Gallant, Litjens V. ; L'érythroblastopénie induite par les érythropoïétines recombinantes ; Pharmactuel, pp.136-145, 2003.

A. Gascon, Clinical experience with ZARZIO® in Europe : what have we learned ? ; Support Care Cancer, pp.2925-2932, 2013.

A. Gascon, Development of a new G-CSF product based on biosimilarity assessment ; Annals of oncology, pp.1419-1429, 2010.

A. Gascon, Presently available biosimilars in hematology-oncology: G-CSF, Targeted Oncology, vol.10, issue.7, pp.29-34
DOI : 10.1007/s11523-011-0190-9

B. Glauser, B. Vairo, S. Oliveira, L. Cinelli, and M. Pereira, Mourão P ; Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: Similarity to the original drug ; ThrombHaemost, pp.302-314, 2012.

W. Jeske, J. Walenga, D. Hoppensteadt, and J. Fareed, Update on the safety and bioequivalence of biosimilars-focus on enoxaparin ; Drug, Healthcare and Patient Safety, pp.133-141, 2013.

A. Kanase, Biosimilars : an overview ; IJPSR, pp.2132-2144, 2013.

B. Kaffenberger and T. Bekaii-saab, Recurrent Life-Threatening Deep Tissue Hematomas After Switching to Generic Enoxaparin: A Report and Perspective on the Approval Process for Biological Compounds, Clinical and Applied Thrombosis/Hemostasis, vol.59, issue.1, pp.104-110, 2012.
DOI : 10.1177/1076029611416641

P. Kaurchugh and V. Roy, Biosimilars : Current Scientific and Regulatory Considerations, Current Clinical Pharmacology, vol.2014, issue.9, pp.53-63

M. Kuhlmann and A. Covic, The protein science of biosimilars, Nephrology Dialysis Transplantation, vol.21, issue.Supplement 5, pp.4-8, 2006.
DOI : 10.1093/ndt/gfl474

D. Mager and W. Jusko, General pharmacokinetic model for drugs exhibiting target-mediated drug disposition, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.6, pp.507-532, 2001.
DOI : 10.1023/A:1014414520282

I. Macdougall, Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights, Kidney International, vol.81, issue.8, pp.727-732, 2012.
DOI : 10.1038/ki.2011.500

A. Manko, A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization, Pharmacological Reports, vol.66, issue.2, pp.239-242, 2014.
DOI : 10.1016/j.pharep.2013.09.005

M. Mccamish and G. Woollett, The state of art in the development of biosimilars ; Clinical Pharmacology and therapeutics, pp.405-417, 2012.

H. Mellstedt, D. Niederwieser, and H. Ludwig, The challenge of biosimilars ; Annals of oncology, pp.411-419, 2007.

A. Nelson, E. Dhimolea, and J. Reichert, Development trends for human monoclonal antibody therapeutics, Nature Reviews Drug Discovery, vol.25, issue.10, pp.767-774, 2010.
DOI : 10.1038/nrd3229

P. Nelson, G. Reynolds, E. Waldrom, and E. Ward, Demystified ...: Monoclonal antibodies, Molecular Pathology, vol.53, issue.3, pp.111-118, 2000.
DOI : 10.1136/mp.53.3.111

D. Niederwieser, Biosimilar agents in oncology/haematology: from approval to practice, European Journal of Haematology, vol.449, issue.4, pp.277-288, 2011.
DOI : 10.1111/j.1600-0609.2010.01566.x

C. Nick, Considerations in the clinical development of biotech medicines ; Regulatory Rapporteur, pp.5-7, 2013.

C. Njue, Statistical considerations for confirmatory clinical trials for similar biotherapeutic products, Biologicals, vol.39, issue.5, pp.266-269, 2011.
DOI : 10.1016/j.biologicals.2011.06.006

G. Paintaud, F. Lejarre, D. Ternant, and P. Goupille, Watier H ; Les anticorps monoclonaux : une avancée thérapeutique récente et majeure, Janvier-Février, vol.64, issue.1, pp.1-7, 2009.
DOI : 10.2515/therapie/2009008

T. Prueksaritanont and C. Tang, ADME of biologics-What Have We Learned from Small Molecules ? The AAPS Journal, pp.410-419, 2012.

L. Puig, Biosimilars in dermatology : Starting with infliximab ; Actasdermosifiliogr, pp.104-175, 2013.

S. Roger, Biosimilars : How similar or dissimilar are they ?; Nephrology, pp.341-346, 2006.

S. Roger and A. Mikhail, Biosimilars : Opportunity or Cause of Concerns ?, J Phar PharmaceutSci, vol.10, issue.3, pp.405-410, 2007.

. Rosenberg, Effects of protein aggregates: An immunologic perspective, The AAPS Journal, vol.8, issue.3, p.59, 2006.
DOI : 10.1208/aapsj080359

N. Sahoo, K. Choudhury, and P. Manchikanti, Manufacturing of Biodrugs, BioDrugs, vol.8, issue.11, pp.217-218, 2009.
DOI : 10.2165/11317110-000000000-00000

G. Shankar and C. Pendley, A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nature Biotechnology, vol.109, issue.5, pp.555-560, 2007.
DOI : 10.1038/nbt1303

H. Schellekens, Biosimilarstherapeuctics : what do we need to consider ?, Nephrology Dialysis Tranplantation, vol.2, issue.1, pp.27-36, 2009.

H. Schellekens, Bioequivalence and the immunogenicity of biopharmaceuticals, Nature Reviews Drug Discovery, vol.1, issue.6, pp.457-62, 2002.
DOI : 10.1038/nrd818

H. Shellekens, Follow-on biologics: challenges of the 'next generation', Nephrology Dialysis Transplantation, vol.20, issue.suppl_4, pp.31-36, 2005.
DOI : 10.1093/ndt/gfh1085

H. Schellekens, Factors influencing the immunogenicity of therapeutic proteins, Nephrology Dialysis Transplantation, vol.20, issue.suppl_6, pp.3-9, 2005.
DOI : 10.1093/ndt/gfh1092

H. Schellekens, Biosimilar epoetins, Eur J Hosp Pharm, vol.3, pp.8-12, 2004.
DOI : 10.1007/978-3-7643-8698-6_7

F. Sorgel, U. Thyroff-friesinger, A. Vetter, B. Venscapell, and M. Kinsig, Bioequivalence of HX 575 (recombinant human epoietin alpha) and a comparator epoietin alpha after Page 185

F. Sorgel, U. Thyroff-friesinger, A. Vetter, B. Venscapell, and M. Kinsig, Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial, BMC Clinical Pharmacology, vol.18, issue.2, p.10, 2009.
DOI : 10.1093/ndt/18.2.353

A. Supersaxo, W. R. Hein, and H. Steffen, Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration, Pharmaceutical Research, vol.07, issue.2, pp.167-176, 1990.
DOI : 10.1023/A:1015880819328

P. Swann and M. Shapiro, Regulatory considerations for development of bioanalytical assays for biotechnology products, Bioanalysis, vol.3, issue.6, pp.597-603, 2011.
DOI : 10.4155/bio.11.27

Y. Vugmeyster, D. Defranco, P. Szklut, Q. Wang, and X. Xu, Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology, J PharmSci, vol.99, pp.1028-1045, 2010.

Y. Vugmeyster, X. Xu, F. P. Theil, L. Khali, and M. Leach, Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges, World Journal of Biological Chemistry, vol.3, issue.4, pp.73-92, 2012.
DOI : 10.4331/wjbc.v3.i4.73

C. Waller, M. Bronchud, S. Mair, and R. Challand, Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial, Annals of Hematology, vol.19, issue.Suppl 1, pp.971-978, 2010.
DOI : 10.1007/s00277-010-0973-6

URL : https://hal.archives-ouvertes.fr/hal-00549425

D. Wang, S. Zhang, H. Zhao, A. Men, and K. Parivar, Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials, The Journal of Clinical Pharmacology, vol.56, issue.4, pp.1012-1036, 2009.
DOI : 10.1177/0091270009337512

C. Warnke, C. Hermanrud, M. Lundkvist, and A. Fogdell-hahn, Anti-Drug Antibodies ; Drugs and Therapy Studies, pp.56-63, 2012.

J. Warren, Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?, British Journal of Clinical Pharmacology, vol.365, issue.1, pp.7-14
DOI : 10.1111/j.1365-2125.2012.04323.x

M. Weise, Biosimilars: what clinicians should know, Blood, vol.120, issue.26, pp.5111-5116, 2012.
DOI : 10.1182/blood-2012-04-425744

L. Zhao, T. Ren, and D. Wang, Clinical Pharmacology considerations in biologics development ; ActapharmacologicaSinica ; September2012, pp.1339-1347

S. Zhang, R. Shi, C. Li, K. Parivar, and D. Wang, Fixed Dosing Versus Body Size-Based Dosing of Therapeutic Peptides and Proteins in Adults, The Journal of Clinical Pharmacology, vol.45, issue.1, pp.18-28, 2012.
DOI : 10.1177/0091270010388648